Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 61–80 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 2NCT03725761 ↗
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Scott T. TagawaPI
Intervention
Drug: Sacituzumab Govitecan
Dates
Oct 2018 – Apr 2024

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 61–80 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 2NCT03725761 ↗
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Scott T. TagawaPI
Intervention
Drug: Sacituzumab Govitecan
Dates
Oct 2018 – Apr 2024

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

· Results posted

Sponsor

University of Wisconsin

Prostate Cancer

Active, not recruitingInterventional · Not applicableNCT03732794 ↗

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery

Leonard N GirardiPI

Intervention: Device: AtriCure CryoICE & AtriClip LAA Exclusion
Dates: Jan 2019 – Jun 2024
Sponsor: AtriCure, Inc.

Atrial Fibrillation (AF)Persistent Atrial FibrillationLongstanding Persistent Atrial Fibrillation

Active, not recruitingInterventional · Phase 3NCT03737981 ↗

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: Venetoclax
Dates: Jan 2019 – Jan 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

RecruitingInterventional · Phase 2NCT03739814 ↗

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Ellen K. RitchiePI

Intervention: Procedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Biological: Inotuzumab Ozogamicin · Procedure: Lumbar Puncture · Drug: Ponatinib
Dates: May 2019 – Feb 2027 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

Active, not recruitingInterventional · Not applicableNCT03754114 ↗

Brain Oxygen Optimization in Severe TBI (BOOST3): A Comparative Effectiveness Study to Test the Efficacy of a Prescribed Treatment Protocol Based on Monitoring the Partial Pressure of Brain Tissue Oxygen.

Margaret HuynhPI

Intervention: Other: ICP + PbtO2 guided management strategy · Other: ICP guided management strategy
Dates: Aug 2019 – Nov 2027 (est.)
Sponsor: National Institute of Neurological Disorders & Stroke

Brain Injuries, Traumatic

Active, not recruitingInterventional · Phase 3NCT03765918 ↗

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Doru PaulPI

Intervention: Biological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2
Dates: Dec 2018 – Jul 2024· Results posted
Sponsor: Merck Sharp & Dohme Corp

Head and Neck Neoplasms

Active, not recruitingInterventional · Phase 3NCT03767244 ↗

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Jim C. HuPI

Intervention: Drug: Apalutamide · Drug: Androgen Deprivation Therapy (ADT) · Drug: Placebo
Dates: Jun 2019 – Dec 2026 (est.)
Sponsor: Janssen Research & Development, LLC

Prostatic Neoplasms

Active, not recruitingInterventional · Phase 2NCT03767348 ↗

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]

Anna C PavlickPI

Intervention: Biological: RP1 · Biological: nivolumab
Dates: Sep 2017 – Jun 2028 (est.)
Sponsor: Replimune Inc.

Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more

Active, not recruitingInterventional · Phase 3NCT03793166 ↗

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Ana M. MolinaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Jun 2019 – Mar 2028 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Clear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more

Active, not recruitingInterventional · Phase 3NCT03803553 ↗

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Manish A ShahPI

Intervention: Drug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + Pertuzumab
Dates: Apr 2020 – Dec 2026 (est.)
Sponsor: The General Hospital Corporation (dba Massachusetts General Hospital)

Metastatic Colon CancerStage III Colon Cancer

RecruitingInterventional · Phase 2NCT03804944 ↗

Converting HR+ Breast Cancer Into an Individualized Vaccine

Silvia Chiara FormentiPI

Intervention: Radiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301
Dates: Mar 2020 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer

RecruitingInterventional · Phase 3NCT03808922 ↗

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Rosy Priya L KodiyanplakkalPI

Intervention: Drug: DAS181 · Drug: Placebo · Drug: DAS181 COVID-19 · Drug: DAS181 OL
Dates: May 2019 – Sep 2028 (est.)
Sponsor: Ansun BioPharma, Inc.

Lower Respiratory Tract InfectionParainfluenzaImmunocompromised+1 more

Active, not recruitingInterventional · Phase 3NCT03811015 ↗

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Hani Lamie AshamallaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission Tomography
Dates: Aug 2019 – Jan 2030 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

RecruitingInterventional · Phase 1NCT03816345 ↗

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Ashish SaxenaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cabozantinib · Drug: Fluoropyrimidine · Biological: Ipilimumab · Biological: Nivolumab · Drug: Platinum Compound · Drug: Platinum Doublet
Dates: Jul 2019 – Mar 2028 (est.)
Sponsor: National Cancer Institute

Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more

Active, not recruitingInterventional · Phase 2NCT03817398 ↗

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Other: Drug Withdrawn · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Tyrosine Kinase Inhibitor
Dates: Nov 2019 – Sep 2026 (est.)
Sponsor: Children's Oncology Group

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Active, not recruitingInterventional · Phase 3NCT03833154 ↗

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation

Silvia Chiara FormentiPI

Intervention: Drug: Durvalumab · Other: Placebo · Drug: (Osimertinib cohort, single-arm, open-label separate cohort)
Dates: Mar 2019 – Oct 2028 (est.)
Sponsor: AstraZeneca, PLC

Carcinoma, Non-Small-Cell Lung

RecruitingInterventional · Phase 2NCT03866382 ↗

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Cora SternbergPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography
Dates: May 2019 – Feb 2027 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more

Active, not recruitingInterventional · Phase 2NCT03888105 ↗

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

John AllanPI

Intervention: Drug: Odronextamab
Dates: Nov 2019 – Jun 2026
Sponsor: Regeneron Pharmaceuticals, Inc.

B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingInterventional · Phase 2NCT03899155 ↗

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Ana M. MolinaPI

Intervention: Drug: Nivolumab · Drug: Ipilimumab · Drug: Cabozantinib · Drug: Trametinib · Drug: Relatlimab · Drug: Nivolumab + Relatlimab · Drug: Capecitabine · Drug: Bevacizumab · Drug: Temozolomide · Drug: Rucaparib · Drug: Daratumumab · Drug: Regorafinib · Drug: Leucovorin · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Enzalutamide · Drug: Sunitinib · Drug: Pemetrexed · Drug: Pembrolizumab
Dates: Aug 2019 – Aug 2029 (est.)
Sponsor: Bristol-Myers Squibb Company

Cancer

Active, not recruitingInterventional · Phase 3NCT03900429 ↗

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Sonal KumarPI

Intervention: Drug: MGL-3196 · Drug: Placebo · Procedure: Liver Biopsy
Dates: Mar 2019 – Jan 2028 (est.)
Sponsor: Madrigal Pharmaceuticals, Inc.

NASH - Nonalcoholic Steatohepatitis

‹ Prev 1 2 3 4 5…56 57 58 59 60 Next ›